Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up after single administration of RV-001 in retinitis pigmentosa
jRCT2033260402Recruiting
- Sponsor
- Restore Vision Inc.
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of teprotumumab in retinitis pigmentosa (RP), sponsored by Restore Vision Inc. Primary endpoint: Treatment-Emergent Adverse Events (TEAEs). Started Jul 2025; status: recruiting.
02
Drugs
teprotumumab
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on jRCT2033260402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033260402.